Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is expected to have strong revenue growth due to its portfolio of aortic-centric solutions, specifically its Aortic Heart Valve, Mitral Heart Valve, and Aortic Allograft products. The company's growth is also supported by its expansion into international markets, with North America being its largest revenue contributor. Additionally, Artivion's recent product launches and upcoming product approvals, such as its NEXUS platform targeting chronic dissection patients, have the potential to drive further revenue growth and margin improvement. Despite some short-term challenges, AORT shares are now undervalued relative to peers, presenting a potential investment opportunity.

Bears say

Artivion is currently facing temporary issues with an isolated stent graft supplier capacity problem and challenges related to their new AMDS product, but these issues are expected to be resolved with the recent PMA approval and adjustments to payment terms. Their upcoming NEXUS launch and anticipated exit of a competitor in the mechanical valve market will provide a growth driver, and the company has a strong pipeline for future product launches and international expansion. However, they do face risks related to international revenues, tissue preservation services, and quality and regulatory issues.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.